Answers are grounded in this paper and cite their sources.
With proper counseling and identification of treatment goals patients with cT0 after neoadjuvant chemotherapy for muscle invasive bladder cancer may have the option to retain the bladder with durable survival. Larger studies are needed to identify possible predictors of response on the clinical, pathological and molecular levels.
No takes yet. Share an insight, caveat, or question.
Meyer et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: